Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
1. Ikena and Inmagene merged, forming ImageneBio, Inc., trading as 'IMA'. 2. A $75 million private placement completed to fuel IMG-007 development. 3. ImageneBio will advance IMG-007 in Phase 2b clinical trials for atopic dermatitis. 4. The merger gives Inmagene approx. 43.1% equity; Ikena holds 35.3%. 5. Reverse stock split of 1-for-12 shares was executed prior to merger completion.